0
     

Report Added
Report already added
Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 15, 10, 1, 32, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alopecia - Overview
Alopecia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alopecia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alopecia - Companies Involved in Therapeutics Development
Alopecia - Drug Profiles
Alopecia - Dormant Projects
Alopecia - Discontinued Products
Alopecia - Product Development Milestones
Featured News & Press Releases
Mar 26, 2022: Nearly 40% of adults with alopecia areata taking OLUMIANT 4-mg saw at least 80% scalp hair coverage at 52 weeks in Lilly's pivotal phase 3 studies
Mar 07, 2022: Kintor concludes enrolment of Phase II alopecia trial in China
Mar 06, 2022: Completion of patient enrollment in phase II clinical trial of KX-826 in China for the treatment of AGA in female patients
Mar 02, 2022: Kintor begins dosing Phase II androgenic alopecia treatment trial in US
Feb 04, 2022: Kintor doses first subject in US Phase I trial of dermatology asset
Feb 03, 2022: Kintor Pharmaceutical: Voluntary announcement first subject dosing in phase I clinical trial of GT20029 (ar-protac) in the United States
Jan 25, 2022: Hope Medicine announces US FDA clearance for phase II clinical trial of a first-in-class monoclonal antibody, HMI-115, in androgen alopecia
Jan 11, 2022: 3SBio announces submission and acceptance of the application for the market launch of 5% Minoxidil foam
Jan 04, 2022: Concert Pharmaceuticals completes enrollment in THRIVE-AA2 phase 3 clinical trial evaluating CTP-543 for Alopecia Areata
Jan 03, 2022: Kintor begins dosing in androgenic alopecia treatment trial in China
Nov 24, 2021: Kintor Pharma receives IND clearance by NMPA for KX-826's pivotal study to treat male alopecia patients
Nov 15, 2021: AnaptysBio announces positive rosnilimab healthy volunteer phase 1 top-line data
Nov 12, 2021: Kintor Pharma announces dosing of first patient in phase II clinical trial of KX-826 for the treatment of androgenic alopecia female patients in China
Oct 25, 2021: Concert Pharmaceuticals completes enrollment in THRIVE-AA1 phase 3 clinical trial evaluating CTP-543 for alopecia areata
Sep 30, 2021: OLUMIANT significantly improved hair regrowth to at least 80% scalp coverage as early as 24 weeks across first completed phase 3 studies for alopecia areata
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Alopecia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Alopecia - Pipeline by 3SBio Inc, 2022
Alopecia - Pipeline by Aclaris Therapeutics Inc, 2022
Alopecia - Pipeline by Addpharma Inc, 2022
Alopecia - Pipeline by Akaal Pharma Pty Ltd, 2022
Alopecia - Pipeline by Alexion Pharmaceuticals Inc, 2022
Alopecia - Pipeline by Almirall SA, 2022
Alopecia - Pipeline by AnaptysBio Inc, 2022
Alopecia - Pipeline by Aneira Pharma Inc, 2022
Alopecia - Pipeline by AnTolRx Inc, 2022
Alopecia - Pipeline by Applied Biology Inc, 2022
Alopecia - Pipeline by Berg LLC, 2022
Alopecia - Pipeline by Biolab Sanus Farmaceutica Ltda, 2022
Alopecia - Pipeline by BiologicsMD Inc, 2022
Alopecia - Pipeline by Bioquark Inc, 2022
Alopecia - Pipeline by BirchBioMed Inc, 2022
Alopecia - Pipeline by Caregen Co Ltd, 2022
Alopecia - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Alopecia - Pipeline by CK Regeon Inc, 2022
Alopecia - Pipeline by Concert Pharmaceuticals Inc, 2022
Alopecia - Pipeline by Cosmo Pharmaceuticals NV, 2022
Alopecia - Pipeline by Dermaliq Therapeutics Inc, 2022
Alopecia - Pipeline by dNovo Inc, 2022
Alopecia - Pipeline by Eli Lilly and Co, 2022
Alopecia - Pipeline by Energenesis Biomedical Co Ltd, 2022
Alopecia - Pipeline by Equillium Inc, 2022
Alopecia - Pipeline by Exicure Inc, 2022
Alopecia - Pipeline by Follica Inc, 2022
Alopecia - Pipeline by Haplnscience Inc, 2022
Alopecia - Pipeline by HCell Inc, 2022
Alopecia - Pipeline by HCW Biologics Inc, 2022
Alopecia - Pipeline by Hope Medicine Inc, 2022
Alopecia - Pipeline by Horizon Therapeutics Plc, 2022
Alopecia - Pipeline by Inventage Lab Inc, 2022
Alopecia - Pipeline by Japan Tobacco Inc, 2022
Alopecia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Alopecia - Pipeline by JN Biosciences LLC, 2022
Alopecia - Pipeline by Johnson & Johnson, 2022
Alopecia - Pipeline by JW Pharmaceutical Corp, 2022
Alopecia - Pipeline by Kedi Biomedical Co Ltd, 2022
Alopecia - Pipeline by Kintor Pharmaceutical Ltd, 2022
Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
Alopecia - Pipeline by LG Chem Ltd, 2022
Alopecia - Pipeline by Maxinovel Pharmaceuticals, 2022
Alopecia - Pipeline by METiS Pharmaceuticals, 2022
Alopecia - Pipeline by Mirae Cell Bio Co Ltd, 2022
Alopecia - Pipeline by Nepsone ehf, 2022
Alopecia - Pipeline by OliX Pharmaceuticals Inc, 2022
Alopecia - Pipeline by Omega Therapeutics Inc, 2022
Alopecia - Pipeline by OnQuality Pharmaceuticals LLC, 2022
Alopecia - Pipeline by Pfizer Inc, 2022
Alopecia - Pipeline by Phio Pharmaceuticals Corp, 2022
Alopecia - Pipeline by Ponce Therapeutics Inc, 2022
Alopecia - Pipeline by ProTransit Nanotherapy LLC, 2022
Alopecia - Pipeline by RiverTown Therapeutics Inc, 2022
Alopecia - Pipeline by Samson Clinical Pty Ltd, 2022
Alopecia - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Alopecia - Pipeline by siRNAgen Therapeutics Corp, 2022
Alopecia - Pipeline by Sisaf Ltd, 2022
Alopecia - Pipeline by Soterios Ltd, 2022
Alopecia - Pipeline by Stemson Therapeutics Corp, 2022
Alopecia - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Alopecia - Pipeline by TagCyx Biotechnologies, 2022
Alopecia - Pipeline by Technoderma Medicines Inc, 2022
Alopecia - Pipeline by Throne Biotechnologies Inc, 2022
Alopecia - Pipeline by Tigo GmbH, 2022
Alopecia - Pipeline by Triple Hair Inc, 2022
Alopecia - Pipeline by Tritech Biopharmaceuticals Co Ltd, 2022
Alopecia - Pipeline by Turn Biotechnologies Inc, 2022
Alopecia - Pipeline by VasoDynamics Ltd, 2022
Alopecia - Dormant Projects, 2022
Alopecia - Dormant Projects, 2022 (Contd..1)
Alopecia - Dormant Projects, 2022 (Contd..2)
Alopecia - Dormant Projects, 2022 (Contd..3)
Alopecia - Discontinued Products, 2022

List of Figures
Number of Products under Development for Alopecia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline